In today’s second full committee hearing on drug pricing held before the US Senate Committee on Finance, executives representing 7 drug makers provided testimony on the high prices of their products.
In today’s second full committee hearing on drug pricing held before the US Senate Committee on Finance, executives representing 7 drug makers provided testimony on the high prices of their products.
Senator Chuck Grassley, R-Iowa, chair of the committee, opened the hearing by warning the witnesses that “We’ve all seen the finger-pointing. Every link in the supply chain has gotten skilled at finger-pointing” on the matter of high prices, and that Congress has grown tired of “the blame game” and seeks substantive answers to its questions.
Before turning to Richard A. Gonzalez, chairman and chief executive officer (CEO) of AbbVie, for his testimony, ranking member Senator Ron Wyden, D-Oregon, raised what he called “troubling information” about AbbVie’s Humira, noting that the company has increased its price for the brand-name adalimumab even as it tied its executives’ bonuses to Humira’s sales.
Gonzalez did not comment on the issue of Humira-linked bonuses in his prepared testimony, saying instead that the Medicare Part D benefit design is to blame for rising out-of-pocket costs for many seniors. High drug prices, said Gonzalez, must be part of a discussion about what patients pay for their drugs, but Part D, he noted, does not reflect the discounts that plans receive from drug makers.
During questioning from senators, Gonzalez defended Humira’s patent estate, saying that AbbVie’s portfolio evolved as the company discovered Humira’s applications in various disease states. “Humira is like 9 different drugs,” he said, given its broad range of therapeutic applications.
Gonzalez also called recent settlements with biosimilar developers a “reasonable balance” that will allow for market entry after patents on adalimumab expire. “We don’t block any biosimilars…We’ve given license to every biosimilar player but 1,” he stated.
In his testimony, Pascal Soriot, executive director and CEO of AstraZeneca, laid blame for high out-of-pocket costs on the current rebate system, which he called unsustainable. He called on the United States to move away from the rebate system and, if that proves to be impossible, to dedicate a portion of discounts and rebates to instituting caps on out-of-pocket spending for patients. He also said that biosimilars could create better competition, and he cited European biosimilar discounts of 40% to 80% as examples of what the United States could save.
Albert Bourla, DVM, PhD, CEO of Pfizer, said that he supports passing all rebates to patients. Currently, the rebates are “swallowed up by the supply chain,” he said, agreeing on the need to cap seniors’ out-of-pocket costs. He also joined Soriot in calling on Congress to “knock down barriers” to biosimilars.
Kenneth C. Frazier, chairman and CEO of Merck, voiced support for greater biosimilar utilization and generic competition, and added that the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act could help facilitate both. He also called on Congress to address regulatory obstacles to value-based contracts.
Several drug makers were united in their opposition to the Trump administration’s proposed International Pricing Index (IPI) plan, which would link drug prices in the United States to prices paid in other countries.
Giovanni Caforio, MD, chairman of the board and CEO of Bristol-Myers Squibb, called on policy makers not to “stifle” the market by implementing the IPI model. Olivier Brandicourt, MD, CEO of Sanofi, added that, “I understand the anger” over rising out of pocket costs, and said that Sanofi could support solutions that accrue savings to patients, but said that the government should not try to directly affect the price of drugs by “outsourcing price decision to other countries.” Finally, Jennifer Taubert, executive vice president and worldwide chairman of Janssen, added that she sees a need for an “American solution to an American challenge.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.